IC 100 reduces inflammasome activation, alpha-synuclein clumps

Blocking the inflammatory protein ASC with IC 100, ZyVersa Therapeutics’ experimental therapy to reduce inflammation, prevented the activation of the inflammasome in microglia — the brain’s resident immune cells — and the start and perpetuation of an inflammatory response. That’s according to results from a study announced by the…

Parkinson’s therapy slows alpha-synuclein spread in mice: Data

Nitrase Therapeutics’ NDC-0524, an antibody therapy for Parkinson’s disease, significantly reduced alpha-synuclein aggregation and spreading in mouse models of the disease, according to preclinical data released by the company. The antibody targets nitrated alpha-synuclein, a misfolded form of the protein that forms toxic clumps in dopaminergic neurons, the nerve cells…

Alpha-synuclein clumps may form in kidneys before traveling to brain

People with chronic kidney disease, a condition characterized by a progressive loss of kidney function, have alpha-synuclein protein deposits in their kidneys, a study in China has found. Alpha-synuclein is a key marker of Parkinson’s disease, suggesting a possible link between kidney function and the neurodegenerative condition. “These findings are…

Chaperone proteins may help lower alpha-synuclein in Parkinson’s

Higher levels of proteins called chaperones are linked with lower levels of disease-driving toxic protein clumps in the brains of people with Parkinson’s disease, a new study shows. The findings suggest that increasing chaperone proteins may be a viable therapeutic strategy for Parkinson’s. Data from the study also revealed…